Vertex Rockets On Strong Cystic Fibrosis Drug Data

Vertex Pharmaceuticals (VRTX) stock rocketed nearly 26% late Tuesday after the biotech reported positive Phase 1 and 2 results of a triple-pill treatment for cystic fibrosis, rivaling fellow biotech Galapagos.

In after-hours trading on the stock market today, Vertex catapulted 25.6%, near 166, after rising 2.3%, to 132.16, during the regular session. Meanwhile, shares of Galapagos (GLPG) fell a fraction on Vertex's news after riding up 2.4%, to 77.49, before the closing bell.

The...

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

Vertex Pharmaceuticals [+]    VRTX [+]    Phase 1 [+]    Galapagos [+]    GLPG [+]   

More #news: